targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

At the beginning of 2025 I knocked on the door of Cai Lei former executive of a major listed company in Beijing When I entered the room he was par ...

Precision Spine, Inc., a U.S.-based leader in the design, development, and manufacturing of a comprehensive portfolio of innovative spinal pathology devices, announced today that Christopher A.

The S&P BSE Sensex ended the day 566 points or 0.75% up at 76,404, while the NSE Nifty 50 gained 130.7 points or 0.57% higher ...

Introduction Who doesn’t want to live an easy life? The sole reason for Human civilization’s advancement in the technological ...

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...